Cosmos Health (COSM) Non Operating Interest Expenses (2013 - 2026)
Cosmos Health's (COSM) quarterly Non Operating Interest Expenses came in at $602364.0 in Q2 2026, up 54.92% on a YoY basis from $388814.0 in Q2 2025, and up 42.33% quarter-over-quarter from $423229.0 in Q1 2026.
Powered by 
Analysis
Cosmos Health (COSM) Non Operating Interest Expenses (2013 - 2026) Analysis & Trends
Cosmos Health (COSM) has reported Non Operating Interest Expenses for 14 consecutive years, with $602364.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non Operating Interest Expenses rose 54.92% year-over-year to $602364.0; the trailing twelve-month figure through Jun 2026 stood at $2.3 million (up 118.13% YoY), and the FY2025 full-year result was $1.9 million, up 87.68% from the prior year.
- Non Operating Interest Expenses rose to $602364.0 in Q2 2026 per COSM's latest filing, from $423229.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $669150.0 in Q3 2025 and bottomed at $134373.0 in Q1 2023.
- Historically, Non Operating Interest Expenses has averaged $397203.6 across 5 years, with a median of $365630.0 in 2024.
- The sharpest annual moves came in 2023 and 2025: Non Operating Interest Expenses sank 77.0% in 2023, then surged 268.82% in 2025.
- Over 5 years, Non Operating Interest Expenses stood at $622660.0 in 2022, then slumped by 45.93% to $336694.0 in 2023, then fell by 5.03% to $319767.0 in 2024, then soared by 104.77% to $654801.0 in 2025, then dropped by 8.01% to $602364.0 in 2026.
- According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $602364.0, $423229.0, and $654801.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.33 Bn | 38.68 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.05 Bn | 18.16 Bn | 1.46 Bn | 120.70 Mn |
| 3 | Dr Reddys Laboratories | 9.76 Bn | 9.58 Bn | 396.53 Mn | -13.26 Mn |
| 4 | Amneal Pharmaceuticals | 5.38 Bn | 5.25 Bn | 334.51 Mn | - |
| 5 | Bausch Health Companies | 2.27 Bn | 436.38 Mn | 2.10 Bn | 396.00 Mn |
| 6 | Alvotech | 1.51 Bn | 1.37 Bn | 2.56 Mn | -41.02 Mn |
| 7 | Ani Pharmaceuticals | 1.51 Bn | 1.15 Bn | 165.89 Mn | - |
| 8 | Amphastar Pharmaceuticals | 1.03 Bn | 737.26 Mn | 93.47 Mn | 6.66 Mn |
| 9 | Fennec Pharmaceuticals | 393.12 Mn | 351.87 Mn | 17.15 Mn | 3,000.00 |
| 10 | Cosmos Health | 15.08 Mn | 12.63 Mn | 1.51 Mn | 602,364.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 602,364.00 |
| Mar 31, 2026 | 423,229.00 |
| Dec 31, 2025 | 654,801.00 |
| Sep 30, 2025 | 669,150.00 |
| Jun 30, 2025 | 388,814.00 |
| Mar 31, 2025 | 187,107.00 |
| Dec 31, 2024 | 319,767.00 |
| Sep 30, 2024 | 181,429.00 |
| Jun 30, 2024 | 342,446.00 |
| Mar 31, 2024 | 168,672.00 |
| Dec 31, 2023 | 336,694.00 |
| Sep 30, 2023 | 151,274.00 |
| Jun 30, 2023 | 244,135.00 |
| Mar 31, 2023 | 134,373.00 |
| Dec 31, 2022 | 622,660.00 |
| Sep 30, 2022 | 517,660.00 |
| Jun 30, 2022 | 620,914.00 |
| Mar 31, 2022 | 584,176.00 |
| Dec 31, 2021 | 641,127.00 |
| Sep 30, 2021 | 670,282.00 |